Objective: Parkinson’s disease (PD) is a prevalent neurological illness that is typified by bradykinesia, postural instability, tremor, and stiffness. An increasing body of research suggests that curcumin and resveratrol can shield dopaminergic neurons against the neurotoxins that cause 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced cell death. In this paper, we developed and assessed an intranasal curcumin and resveratrol nanoparticle for the treatment of parkisonism.

Background: Among the polyphenolic compounds found naturally in red wine and grapes are resveratrol and curcumin, which have a variety of pharmacological actions such as anti-oxidation, anti-apoptosis, and anti-inflammation. It can also penetrate the blood-brain barrier and dissolve in water, but the amount of resveratrol and curcumin that can enter the brain is restricted. This work offers a novel way to get around these limitations by creating nanosystems that can shield these compounds from extensive metabolism and degradation while also improving their delivery to the brain at the right therapeutic concentration.

Method: Chitosan nanoparticles loaded with resveratrol and curcumin, made via ionic gelation using tripolyphosphate anions. Particle size, loading capacity, zeta potential, entrapment efficiency, in vitro release studies, and in vivo distribution following intranasal injection were all measured for nanoparticles.

Results: It was discovered that the average particle size, polydispersity index (PDI), and encapsulation efficiency were, respectively, 144.7 ± 9.45, 0.470 ± 0.07, and 98.56 ± 3.19. For up to 13 hours, the nanoparticles’ sustained release patterns were seen. Following intranasal injection, the concentrations (% Radioactivity/g) in the brain were found to be considerably increased at all time periods. After intraperitoneal injection, the rats’ liver (8.934 ± 0.66), kidneys (5.129 ± 0.34), gut (3.72 ± 0.23), and lungs (2.207 ± 0.87) had the greatest concentrations of naoparticles. Rats were used for gamma scintigraphy imaging to determine the drug’s location in the brain.

Conclusion: The delivery of chitosan nanoparticles laden with curcumin and resveratrol significantly increased the brain’s bioavailability, according to the data. This might be a major breakthrough in direct brain-to-nose targeting for Parkinson’s disease therapy.

References: Haque S, Md S, Fazil M, et al. Venlafaxine loaded chitosan NPs for brain targeting: pharmacokinetic and pharmacodynamic evaluation. Carbohydr Polym 2012;89:72–9.
Md S, Khan RA, Mustafa G, et al. Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmaco- dynamic, pharmacokinetic and scintigraphy study in mice model. Eur J Pharm Sci 2013;48:393–405.
Calvo P, Remunan-Lopez C, Vila-Jata JL, Alonso MJ. Chitosan and chitosan: ethylene oxide–propylene oxide block copolymer nano- particles as novel carriers for proteins and vaccines. Pharm Res 1997;14:1431–6.
Papadimitriou S, Bikiaris D, Avgoustakis K, et al. Chitosan nanoparticles loaded with dorzolamide and pramipexole. Carbohydr Polym 2008;73:44–54.
Marchal-Heussler L, Maincent P, Hoffman M, et al. Antiglaucomatous activity of betaxolol chlorhydrate sorbed onto different isobutyl cyanoacrylate nanoparticles preparations. Int J Pharm 1990;58:115–22.

« Back to 2024 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/formulations-and-assessments-of-intra-nasal-noses-to-brain-curcumin-delivery-using-reversible-nanoparticles-for-parkinsonism-treatment-a-preclinical-approach/